CIRCULAR FOR THE 2023 ANNUAL GENERAL MEETING AND 2024 FIRST H SHARE CLASS MEETING
PHARMARON: (1) PROPOSED INCREASE IN THE REGISTERED CAPITAL; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
PHARMARON: CLOSURE OF REGISTER OF MEMBERS FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2023 AND THE SECOND H SHARE CLASS MEETING OF 2023
PHARMARON: (1) PROPOSED INCREASE IN THE REGISTERED CAPITAL; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
PHARMARON: FURTHER ADJUSTMENT OF THE CONVERSION PRICE OF US$300.0 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2026 (Debt Stock Code: 40725) AND FURTHER ADJUSTMENT OF THE CONVERSION PRICE OF RMB$1,916.0 MILLION ZERO COUPON US$-SETTLED CONVERTIBLE BONDS DUE 20
PHARMARON: GRANT OF RESTRICTED SHARES UNDER THE FIRST GRANT AND THE RESERVED GRANT UNDER THE 2023 A SHARE INCENTIVE SCHEME
PHARMARON: ANNOUNCEMENT ON THE FINAL NUMBER OF ADDITIONAL CONVERSION SHARES TO BE ISSUED UNDER THE 2022 CONVERTIBLE BONDS-RELATED SPECIFIC MANDATE
PHARMARON: (1) PROPOSED REPURCHASE AND CANCELLATION OF PART OF THE RESTRICTED A SHARES GRANTED UNDER THE 2019 A SHARE INCENTIVE SCHEME; (2) PROPOSED REDUCTION OF THE REGISTERED CAPITAL; AND (3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION BY VIRTUE O
PHARMARON: (1) PROPOSED ADOPTION OF THE 2023 A SHARE INCENTIVE SCHEME AND THE ASSESSMENT MANAGEMENT MEASURES; (2) PROPOSED ISSUE AND GRANT OF THE NEW A SHARES UNDER THE 2023 A SHARE INCENTIVE SCHEME; AND (3) PROPOSED AUTHORIZATION TO THE BOARD TO HANDLE MA
PHARMARON: (1) PROPOSED INCREASE IN THE REGISTERED CAPITAL; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
PHARMARON: PROPOSED GRANT OF THE 2022 CONVERTIBLE BONDS-RELATED SPECIFIC MANDATE TO ISSUE ADDITIONAL H SHARES
Pharmaron Beijing Co., Ltd.*: CLOSURE OF REGISTER OF MEMBERS FOR THE SECOND EXTRAORDINARY GENERAL MEETING OF 2022
Pharmaron Beijing Co., Ltd.*: ADJUSTMENT OF THE CONVERSION PRICE OF US$300.0 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2026 (Debt Stock Code: 40725) AND ADJUSTMENT OF THE CONVERSION PRICE OF RMB$1,916.0 MILLION ZERO COUPON US$-SETTLED CONVERTIBLE BONDS DUE
Pharmaron Beijing Co., Ltd.*: ADJUSTMENT OF THE CONVERSION PRICE OF US$300.0 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2026 (Debt Stock Code: 40725) AND ADJUSTMENT OF THE CONVERSION PRICE OF RMB$1,916.0 MILLION ZERO COUPON US$-SETTLED CONVERTIBLE BONDS DUE
Pharmaron Beijing Co., Ltd.*: ANNOUNCEMENT ON THE FINAL NUMBER OF ADDITIONAL CONVERSION SHARES TO BE ISSUED UNDER THE CONVERTIBLE BONDS-RELATED SPECIFIC MANDATE
Pharmaron Beijing Co., Ltd.*: REPORT OF BOARD & SUPERVISORY COMMITTEE;FINANCIAL STATEMENTS;PROFIT DISTRIBUTION PLAN;GRANT OF CONVERTIBLE BONDS-RELATED SPECIFIC MANDATE;REPORT & ANNUAL RESULTS ANNOUNCEMENT;REMUNERATION OF DIRECTORS & SUPERVISORS;ENGAGEMENT
Pharmaron Beijing Co., Ltd.*: (1) PROPOSED ADOPTION OF THE 2022 A SHARE INCENTIVE SCHEME AND THE ASSESSMENT MANAGEMENT MEASURES; (2) PROPOSED ISSUE AND GRANT OF THE NEW A SHARES UNDER THE 2022 A SHARE INCENTIVE SCHEME PURSUANT TO SPECIFIC MANDATE; AND (3)
Pharmaron Beijing Co., Ltd.*: CLOSURE OF REGISTER OF MEMBERS FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2022 AND THE FIRST H SHARES CLASS MEETING OF 2022
Pharmaron Beijing Co., Ltd.*: (1) PROPOSED REDUCTION OF REGISTERED CAPITAL; (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (3) PROPOSED AMENDMENTS TO VARIOUS SETS OF INTERNAL RULES AND REGULATIONS; AND (4) PROPOSED APPOINTMENT OF INTERNAL CONTROL
Pharmaron Beijing Co., Ltd.*: CLOSURE OF REGISTER OF MEMBERS FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2021 AND THE SECOND H SHARES CLASS MEETING OF 2021
No Data